Equities

Shield Therapeutics PLC

Shield Therapeutics PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)8.95
  • Today's Change-0.05 / -0.56%
  • Shares traded381.23k
  • 1 Year change-79.43%
  • Beta2.2180
Data delayed at least 20 minutes, as of Aug 17 2022 16:28 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Shield Therapeutics plc is a United Kingdom-based commercial-stage specialty pharmaceutical company. The Company specializes in the development and commercialization of late-stage pharmaceuticals which address areas of unmet medical need. The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. Its pipeline product candidate, PT20, is an iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease (CKD). PT20 has completed its Phase II pivotal study. Its subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (Switzerland) AG, Shield TX (UK) Limited, Phosphate Therapeutics Limited and Shield Therapeutics Inc.

  • Revenue in GBP (TTM)1.52m
  • Net income in GBP-19.34m
  • Incorporated2015
  • Employees23.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ovoca Bio PLC0.00-4.42m7.76m10.00--0.6826-----0.0541-0.05650.000.13870.00----0.00-31.04-10.95-32.77-11.66--------5.17--0.00-------129.93--69.52--
Genflow Biosciences PLC-100.00bn-100.00bn8.04m----4,262.64----------0.00001----------------------------0.9711--------------
Evgen Pharma PLC0.00-2.73m9.48m11.00--1.03-----0.0099-0.00990.000.03360.00----0.00-24.76-42.32-25.95-46.45-------6,869.07----0.00---100.00---2.09---47.61--
Midatech Pharma PLC578.00k-5.46m10.59m20.00--0.9892--17.89-0.0734-0.07340.00720.10620.0509--0.719828,900.00-48.04-40.54-61.01-49.01-----944.64-1,301.64----0.0683--68.51-15.2675.39---25.19--
Proteome Sciences plc6.40m560.00k11.05m27.0020.69--11.591.730.00180.00180.0208-0.00860.65142.885.35237,148.105.70-7.87----56.2959.948.75-15.710.3692.761.28--7.9113.33-75.59--43.95--
Abingdon Health PLC5.64m-12.85m11.26m151.00--0.5157--2.00-0.0949-0.09490.030.17940.15810.84210.669937,317.88-36.04---49.56---1.38---228.02--1.48-167.050.0572--121.93---106.69------
Oxford Biodynamics PLC176.00k-6.63m13.80m39.00--2.10--78.40-0.0695-0.06950.00180.06550.0133--0.18324,512.82-50.16-24.63-57.11-26.67-----3,768.18-480.922.80--0.4983---25.22-20.75-53.64--71.53--
Kanabo Group PLC73.00k-4.55m13.96m0.00--2.39--194.08-0.0144-0.01440.00020.0140.0228--0.3296---142.42---153.70--9.59---6,234.25--11.43--0.00-------3,374.05------
Provexis plc479.46k-283.34k14.97m2.00--9.96--32.38-0.0001-0.00010.00020.00070.60280.55874.05239,730.00-37.93-96.20-26.38-55.1389.0189.81-62.92-133.986.32--0.00--45.2340.7016.05------
Shield Therapeutics PLC1.52m-19.34m15.46m23.00--0.3841--10.27-0.0933-0.09330.00750.19010.03950.65030.85666,043.48-50.26-25.36-54.23-27.6235.4886.93-1,272.94-207.404.62--0.0038---85.3837.95-635.21---8.25--
Genincode PLC1.15m-4.14m15.57m20.00--1.17--13.91-0.0432-0.04320.0120.14320.130934.893.5657,700.00-46.98---51.02--51.39---358.93--18.00--0.00--20.11---255.23------
IXICO PLC8.20m949.00k15.65m93.0016.651.369.911.910.01950.01950.16610.23980.6088--2.9988,161.297.041.598.192.1361.5963.7311.562.11--23.000.04510.00-3.5922.9765.44--145.81--
Hemogenyx Pharmaceuticals PLC0.00-5.10m15.92m10.00--1.97-----0.0081-0.00810.000.00840.00----0.00-91.34-96.46-112.36-120.13-----------1.050.0012-------144.89--34.08--
Diurnal Group PLC5.28m-13.34m16.55m36.00--0.5654--3.21-0.0839-0.08390.03350.17690.17340.51987.80146,722.20-43.79-43.08-50.20-50.3383.13---252.54-427.577.13-22.990.00---30.76---146.78------
MiLOC Group Limited514.74k-543.61k17.17m6.00------32.97-0.0064-0.00640.0059-0.04840.5467--11.32---104.65-118.75----16.9638.24-191.43-156.87---------75.86-14.62-156.85------
Data as of Aug 17 2022. Currency figures normalised to Shield Therapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

29.55%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Stockbrokers Ltd.as of 02 May 202213.40m6.20%
Jupiter Asset Management Ltd.as of 30 Apr 202212.11m5.60%
Hargreaves Lansdown Asset Management Ltd.as of 02 May 20227.00m3.24%
JPMorgan Asset Management (UK) Ltd.as of 10 Apr 20186.24m2.89%
Rahn+Bodmer Co.as of 02 May 20225.65m2.61%
USS Investment Management Ltd.as of 19 Mar 20215.07m2.34%
Chelverton Asset Management Ltd.as of 31 Dec 20214.50m2.08%
BlackRock Investment Management (UK) Ltd.as of 02 May 20224.02m1.86%
IG Markets Ltd.as of 02 May 20223.10m1.43%
Jarvis Investment Management Ltd.as of 02 May 20222.82m1.30%
More ▼
Data from 31 Dec 2021 - 02 Aug 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.